Advertisement

Drugs & Therapy Perspectives

, Volume 20, Issue 4, pp 1–4 | Cite as

Adefovir dipivoxil: an effective treatment option for chronic hepatitis B

Drugs and Profile Reports
  • 18 Downloads

Keywords

Lamivudine Adefovir Adefovir Dipivoxil Lamivudine Resistance Differential Feature Table 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dando TM, Plosker, GL. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63 (20): 2215–34.PubMedCrossRefGoogle Scholar
  2. 2.
    British National Formulary. No. 46. London: The Pharmaceutical Press, 2003 SepGoogle Scholar
  3. 3.
    Gilead Sciences Inc. Hepsera (adefovir dipivoxil) full prescribing information. Foster City (CA): Gilead Sciences Inc., 2002 SepGoogle Scholar
  4. 4.
    European Agency for Evaluation of Medicinal Products. Hepsera 10mg: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Dec 5]
  5. 5.
    Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 808–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 800–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [oral presentation]. The 38th Annual Meeting of the European Association for the Study of the Liver; 2003 Mar 29–Apr 1; IstanbulGoogle Scholar
  8. 8.
    Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [abstract no. 492]. J Hepatol 2003 Apr; 38 Suppl. 2: 143CrossRefGoogle Scholar
  9. 9.
    Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003 Jul; 38 (1): 96–103.PubMedCrossRefGoogle Scholar
  10. 10.
    Xiong S, Yang H, Westland CE, et al. Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil [abstract]. J Hepatol 2003; 38 Suppl. 2: 182.CrossRefGoogle Scholar
  11. 11.
    Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract no. 845]. Hepatology 2002 Oct; 36 (Pt 2): 374AGoogle Scholar
  12. 12.
    Willems B, Lau G, Leung N, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52-week results [abstract no. 45 plus poster]. Fourth International Workshop Therapies for Viral Hepatitis; 2002 Oct 29–31; BostonGoogle Scholar
  13. 13.
    Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis [abstract no. 69]. J Hepatol 2003 Apr; 38 Suppl. 2: 25CrossRefGoogle Scholar
  14. 14.
    Heathcote J, Chang T-T, Lim SG, et al. Safety profile of 48 weeks of adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two phase III studies [abstract no. 1882]. Hepatology 2002 Oct; 36 (Pt 2): 633AGoogle Scholar
  15. 15.
    Chang TT, Lim SG, Hadziyannis S, et al. Long-term safety of adefovir dipivoxil (ADV) 10mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase II studies [abstract no. 454]. J Hepatol 2003 Apr; 38 Suppl. 2: 133CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations